Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2022 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
August 01, 2022 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results for Second Quarter 2022

Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segmentResumes financial guidance; provides update to full year...
July 18, 2022 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022

GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial...
July 07, 2022 16:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola

GAITHERSBURG, Md. and MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback...
July 06, 2022 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors

GAITHERSBURG, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Sujata Dayal as a Class II director to...
June 24, 2022 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License...
June 21, 2022 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and...
June 02, 2022 08:20 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
May 16, 2022 06:32 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threatTransaction to be funded...
May 12, 2022 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT

GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live...